Apontis Pharma AG (FRA:APPH)

Germany flag Germany · Delayed Price · Currency is EUR
10.95
0.00 (0.00%)
At close: May 30, 2025, 10:00 PM CET
30.36%
Market Cap 98.29M
Revenue (ttm) 48.47M
Net Income (ttm) 753.57K
Shares Out n/a
EPS (ttm) 0.09
PE Ratio 130.44
Forward PE 36.41
Dividend n/a
Ex-Dividend Date n/a
Volume 10
Average Volume 120
Open 11.20
Previous Close 10.95
Day's Range 10.95 - 11.20
52-Week Range 6.12 - 12.20
Beta n/a
RSI 72.69
Earnings Date Aug 8, 2025

About Apontis Pharma AG

Apontis Pharma AG engages in the marketing and sale of medical drugs for indication fields of internal medicine in Germany. It offers single pills and other pharmaceutical products with a focus on cardiovascular diseases, such as hypertension, hyperlipidemia, and secondary prophylaxis, as well as respiratory diseases and diabetes. The company was founded in 1946 and is based in Monheim am Rhein, Germany. As of November 21, 2024, Apontis Pharma AG operates as a subsidiary of Zentiva AG. [Read more]

Industry Pharmaceutical Preparations
Founded 1946
Employees 137
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol APPH
Full Company Profile

Financial Performance

Financial Statements

News

APONTIS PHARMA: Big 2024 Gains & Merger Plans Ahead!

APONTIS PHARMA has surged ahead with a remarkable 31.1% sales increase, signaling a transformative year for the company. With revenues climbing to EUR 48.5 million and a significant EBITDA turnaround,...

2 months ago - Wallstreet:Online

EQS-News: APONTIS PHARMA with significant sales and earnings increase in 2024 financial year – squeeze-out and merger planned

EQS-News: APONTIS PHARMA AG / Key word(s): Annual Report/Annual Results APONTIS PHARMA with significant sales and earnings increase in 2024 financial year – squeeze-out and merger planned 31.03.2025 /...

2 months ago - Wallstreet:Online